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Abstract Before 2009, nonsmall cell lung cancer (NSCLC)
was one disease entity treated by cytotoxic chemotherapy that
provided a response rate of 20–35 % and a median survival
time (MST) of 10–12 months. In 2004, it was found that
activated mutations of the epidermal growth factor receptor
(EGFR) gene were present in a subset of NSCLC and that
tumors with EGFR mutations were highly sensitive to EGFR
tyrosine kinase inhibitors (TKI). Four phase III studies (North
East Japan (NEJ) 002, West Japan Thoracic Oncology Group
(WJTOG) 3405, OPTIMAL, and EUROTAC) prospectively
compared TKI (gefitinib or erlotinib) with cytotoxic chemo-
therapy as first-line therapy in EGFR-mutated NSCLC. These
studies confirmed that progression-free survival (PFS) with
TKIs (as the primary endpoint) was significantly longer than
that with standard chemotherapy (hazard ratio [HR]=0.16–
0.49) from 2009 to 2011. Although the NEJ 002 study showed
identical overall survival (OS) between the arms (HR=0.89),
quality of life (QoL) was maintained much longer in patients
treated with gefitinib. In conclusion, TKI should be consid-
ered as the standard first-line therapy in advanced EGFR-
mutated NSCLC. Since 2009, a new step has been introduced
in the treatment algorithm for advanced NSCLC.
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Introduction
Recent sequencing of DNA to identify polymorphisms has
catalyzed the quest for protein kinase “driver” mutations,
which contribute to the transformation of a normal cell to a
proliferating cancerous cell. On the other hand, kinase “pas-
senger” mutations are considered to reflect mutations that
merely build up in the course of cancerous cell replication
and proliferation. At present, there are driver mutations in
nonsmall cell lung cancer (NSCLC), such as epidermal
growth factor receptor (EGFR) mutations [1–3], a fusion gene
between echinoderm microtubule-associated protein-like 4
(EML4) and the anaplastic lymphoma kinase (ALK) [4, 5],
and fusion genes with RET proto-oncogene (RET) [6–8], for
which specific agents have been developed. In this manu-
script, a road to personalized therapy by EGFR mutations in
advanced NSCLC, which was the first experience to treat
advanced NSCLC patients individually, is reviewed.
Personalized therapy by EGFR mutations in advanced
NSCLC
Dysregulation of protein kinases is frequently observed in
cancer cells; therefore, protein kinases are attractive targets
in the development of anticancer drugs. Small molecule inhib-
itors that block binding of adenosine-5′-triphosphate (ATP) to
the tyrosine kinase catalytic domain have been developed, and
gefitinib and erlotinib are the first generation of such agents,
which act as tyrosine kinase inhibitors (TKI) at the EGFR. In
2004, three groups of researchers reported that activating
mutations of EGFR detected by direct sequencing were pres-
ent in a subset of NSCLC and that tumors with EGFR muta-
tions were highly sensitive to EGFR-TKI [1–3].
Although this knowledge is the first evidence for division
of subpopulations in NSCLC and of the possibility of treat-
ing NSCLC patients individually, there have been two
streams of clinical studies. Clinical efficacy of EGFR-TKIs
such as gefitinib or erlotinib has been investigated initially
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in unselected patients [9–13] and, subsequently, on the basis
of clinical characteristics [14]. On the other hand, in order to
develop personalized therapy in NSCLC, clinical efficacy of
EGFR-TKIs has been indicated by molecular selection in
phase 3 trials of NSCLC (Table 1) [15–19].
Unselected patients
In the BR.21 phase III comparative study [9], 731 previous-
ly treated NSCLC patients (unselected by EGFR mutations)
were allocated randomly to the erlotinib or placebo groups
at a ratio of 2:1. At the primary endpoints, erlotinib was
significantly superior in terms of both progression-free sur-
vival (PFS) (2.2 months vs. 1.8 months, respectively, hazard
ratio (HR)=0.61, p<0.001) and median survival time
(MST) (6.7 months vs. 4.7 months, respectively, HR=
0.70, p<0.001). On the basis of the results of BR.21, erlo-
tinib has become a standard therapy for previously treated
patients with advanced NSCLC and is now used in previ-
ously treated cases of NSCLC that may or may not have
EGFR mutations.
In order to evaluate gefitinib, a phase III study (Iressa
Survival Evaluation in Advanced Lung Cancer (ISEL)) was
carried out [10]. A total of 1,692 patients refractory to or
intolerant of their latest chemotherapy were randomized to
receive either gefitinib (250 mg/day) or placebo plus best
supportive care (BSC). The primary endpoint, MST, was
5.1 months in the placebo group and 5.6 months in the
gefitinib group, with no significant differences between the
two groups (p=0.087). Therefore, efficacy of gefitinib in
NSCLC patients unselected by EGFR mutations was not
indicated. Another randomized phase III study (INTEREST)
[11] compared gefitinib with standard second-line chemother-
apy using docetaxel in 1,433 previously treated NSCLC
patients unselected by EGFRmutations. As to overall survival
(OS), which was the primary endpoint of the study, the HR
was 1.020 (95 % confidence interval [CI]: 0.905–1.150) and
did not exceed the preset upper limit (1.154), thus endorsing
the noninferiority of gefitinib to docetaxel. However, the V-
15-32 randomized phase III study, which aimed to confirm the
noninferiority of gefitinib to docetaxel in regard to OS [12],
was carried out in Japan and involved 490 previously treated
NSCLC patients unselected by EGFR mutations. MST were
14.0 and 11.5 months for the gefitinib and docetaxel groups,
respectively, and the HR was 1.12 (95 % CI: 0.89–1.40).
Thus, the study did not demonstrate noninferiority of gefitinib
to docetaxel. The potency of gefitinib in unselected patients
with NSCLC is considered to be controversial.
Selection by background
In preplanned subgroup analyses of the ISEL trial men-
tioned above [20], gefitinib was shown to extend survival
in Asian patients (MST: 9.5 months vs. 5.5 months, HR=
0.66, p=0.01). In addition, covariate analyses of demo-
graphic subsets among patients of Asian origin treated with
gefitinib showed a survival advantage (HR<1) across never-
smokers (HR, 0.37; p=0.0004) and adenocarcinoma
patients (HR, 0.54; p=0.0028). Therefore, in March 2006,
the Iressa® Pan-Asia Study (IPASS) was initiated to inves-
tigate the effectiveness of first-line gefitinib in previously
untreated patients in East Asia who had advanced pulmo-
nary adenocarcinoma and who were light or nonsmokers
[14]. The IPASS included 1,217 NSCLC patients selected
by backgrounds and compared gefitinib therapy with carbo-
platin (CBDCA)+paclitaxel (PTX) therapy as a first-line
treatment. As to PFS, which was the primary endpoint of
this study, the HR was 0.741 (95 % CI: 0.651–0.845), and it
was reported that the outcome was significantly better in the
gefitinib group. However, since the survival curves for the
two groups crossed each other, it was difficult to interpret
the value of HR (Fig. 1a). Because Cox analysis should be
used in cases having a constant relationship between HR
and time [21], this could not be used when the curves
crossed each other. For example, PFS of gefitinib was better,
the same, or worse than that of CDBCA+PTX at 12, 6, or
3 months, respectively (Fig. 1a).
Although the result at the primary endpoint in the IPASS
was inconclusive, the importance of the IPASS report is
demonstrated in its subset analyses [14]. Among 1,217
patients enrolled, an EGFR mutation test (amplification
mutation refractory system) was performed on tumor sam-
ples from 437 patients (36 %). In this analysis, the crossing
of the survival curves seen in Fig. 1a disappeared (Fig. 1b,
c). In the subgroup of 261 patients who were positive for
EGFR mutation, PFS was significantly longer among those
who received gefitinib than among those who received
CBDCA–PTX (HR=0.48; P<0.001), whereas in the sub-
group of 176 patients who were negative for the mutation,
PFS was significantly longer among those who received
CBDCA–PTX (HR=2.85; P<0.001). Thus, the critical
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message was that there was no indication for gefitinib in
patients who were negative for the EGFR mutation.
In addition to the EGFR mutation test described above,
the biomarkers analyzed in IPASS were EGFR gene copy
number (fluorescent in situ hybridization (FISH)), and
EGFR protein expression (immunohistochemistry) [22].
PFS was significantly longer with gefitinib in patients
whose tumors had both high EGFR gene copy number and
EGFR mutation (HR, 0.48) but was significantly shorter
when a high EGFR gene copy number was not accompanied
by EGFR mutation (HR, 3.85) (Fig. 2). Among the three
biomarkers, EGFR mutations are the strongest predictive
biomarker for PFS and tumor response to first-line gefitinib
vs. CBDCA+PTX. Selection by backgrounds, Asian origin,
adenocarcinoma histology, and light or nonsmoking resulted
in an EGFR mutation-rich population at a rate of 60 % (261
EGFR-mutated patients/437 patients evaluated). Thus, if the
strategy of selection by backgrounds is employed, there
should be a 40 % risk associated with TKI treatment for
patients without EGFR mutations.
Selection by EGFR mutations
Since 2004 when the pivotal studies reported on the relation-
ship between EGFR mutations and TKI sensitivity, multiple
phase II studies have confirmed a striking response to EGFR-
TKIs in this population in Japan [23–29]. A combined analy-
sis employing these phase II studies, named IRESSA
Combined Analysis of the Mutation Positives (I-CAMP)
study, indicated longer PFS with gefitinib than with standard
chemotherapy [30]. In March 2006, at the same time that the
IPASS study started, two phase III trials, the North East Japan
(NEJ) 002 study and the West Japan Thoracic Oncology
Group (WJTOG) 3405 [16, 17], were initiated, which com-
pared gefitinib with standard chemotherapy in first-line treat-
ment for EGFR-mutated NSCLC (Table 2). NEJ 002 first
confirmed as the primary endpoint that PFS in the gefitinib
group was significantly longer than that in the CBDCA plus
PTX group (10.8 months vs. 5.4 months, HR=0.30, P<0.001)
[15, 16]. In WJTOG3405, the gefitinib group also had signif-
icantly longer PFS compared with the cisplatin plus docetaxel












































Fig. 1 Progression-free survival in IPASS. a Kaplan–Meier curves of
PFS for Asian patients treated with gefitinib or carboplatin plus pacli-
taxel who had pulmonary adenocarcinoma and who were light or
nonsmokers. b and c show PFS for patients with or without EGFR
mutations treated with gefitinib or carboplatin plus paclitaxel, respec-
tively, in subset analyses. [14]
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goup, with a median PFS of 9.2 months vs. 6.3 months (HR
0.489, p<0.0001) [17]. In order to evaluate erlotinib further,
the phase III OPTIMAL study [18] was initiated in August
2008. It compared the PFS of erlotinib with gemcitabine plus
CBDCA in the first-line treatment of Chinese patients with
advanced EGFR mutation-positive NSCLC. The median PFS
was significantly longer in erlotinib-treated patients than in
those on chemotherapy (13.1 vs. 4.6 months; HR=0.16;
p<0.0001). In another phase III study, EURTAC [19], started
in February 2007, PFS with erlotinib was compared with
standard chemotherapy for first-line treatment of European
patients with advanced EGFR mutation-positive NSCLC.
The preplanned interim analysis showed that the median
PFS was 9.7 months in the erlotinib group, compared with
5.2 months in the standard chemotherapy group (HR=0.37;
p<0.0001).
OS was retrospectively compared between advanced
NSCLC patients with sensitive EGFR mutations who began
first-line systemic therapy before and after gefitinib approval
in Japan (January 1999–July 2001 and July 2002–December
2004, respectively) [31]. In 136 (41 %) of the 330 patients
treated at the National Cancer Center Hospital of Japan,
although no significant survival improvement was observed
in patients without EGFR mutations (MST: 13.2 vs.
10.4 months, respectively; P=0.13), OS was significantly
longer among the EGFR-mutant patients treated after gefitinib
approval compared with the OS of patients treated before
gefitinib approval (MST: 27.2 vs. 13.6 months, respectively;
P<0.001). However, a combined analysis of ICAMP and a
post hoc analysis of IPASS suggested identical survival of
patients on gefitinib and chemotherapy in first-line treatment
for EGFR-mutated patients [30, 32]..Furthermore, a secondary
endpoint of both NEJ 002 [33] and WJTOG3405 [34] pro-
spectively showed identical OS between gefitinib and chemo-
therapy in first-line treatment of NSCLC patients harboring
sensitive EGFR mutations (Table 2), although OS data from
OPTIMAL and EURTAC are immature at the present time. It
must be explained that in almost all of the patients who were
treated with first-line chemotherapy in NEJ 002 and WJTOG
3405, a crossover treatment with gefitinib was undertaken.
Therefore, from the viewpoint of OS, the effect of gefitinib is
additive to that of chemotherapy, indicating that both first-line
and second-line gefitinib are acceptable.
When OS is identical between two arms, improvement in
quality of life (QoL) and disease-related symptoms are among
the key goals in the treatment of NSCLC. IPASS reported better
QoL in EGFR-mutated patients treated with gefitinib than in
those treated with CBDCA+PTX, but this analysis was a post
hoc estimation [35]. With the exception of WJTOG3405, the
Table 2 Phase III studies of
TKI for EGFR-mutated patients
*shows a significant difference
between arms
Trial Arm Number RR PFS OS Ref.
NEJ 002 Gefitinib 114 74 % 10.8 m 27.7 m NEJM (2010)
CbPXL 110 31 % 5.4 m 26.6 m OS: Ann Oncol. (in press)
HR=0.30* HR=0.89 QOL: Oncologist (2012)
WJTOG 3405 Gefitinib 86 62 % 9.2 m 36 m Lancet Oncol (2010)
CisDTX 86 32 % 6.3 m 39 m OS: ASCO (2012)
HR=0.49* HR=1.19
OPTIMAL Erlotinib 83 83 % 13.1 m NR Lancet Oncol (2011)
CbGEM 82 36 % 4.6 m NR QOL: ASCO (2012)
HR=0.16*
EURTAC Erlotinib 86 58 % 9.7 m NR Lancet Oncol (2012)
Pt doublet 87 15 % 5.2 m NR
HR=0.37*
0.5 1.0 2.0 4.0
Evaluable mutation status
EGFR mutation +





EGFR mutation  
EGFR expression 
Hazard ratio (gefitinib : carboplatin / paclitaxel) and 95% CI




Non-evaluable gene copy status
Fig. 2 Biomarker for gefitinib. In comparing EGFR mutation, EGFR
gene copy number, and EGFR expression status, EGFR mutation is the
best biomarker for gefitinib. [22]
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other three trials listed in Table 2 prospectively investigated
QoL of NSCLC patients with sensitive EGFR mutations who
were treated with EGFR-TKI or standard chemotherapy, and
NEJ 002 and OPTIMAL have presented the results [36, 37]. In
NEJ 002, patients’ QoL was assessed weekly using the Care
Notebook [38], and the primary endpoint of the QoL analysis
was time to deterioration from baseline on each of the physical,
mental, and life well-being QoL scales. Kaplan–Meier proba-
bility curves and logrank tests showed that time to defined
deterioration in physical and life well-being significantly fa-
vored gefitinib over chemotherapy (HR=0.34; p<0.0001 and
HR, 0.43; p<0.0001, respectively); this indicated that QoL was
maintained much longer in patients treated with gefitinib than
in those treated with standard chemotherapy [36]. In
OPTIMAL, the Functional Assessment of Cancer Therapy
(FACT) measuring system showed that compared with the
gemcitabine/CBDCAgroup, the erlotinib group had a clinically
relevant improvement in QoL, as assessed by scores on the
FACT-L (73 % vs. 29.6 %; odds ratio (OR)=6.9; p<0.0001),
the LCSS (75.7 % vs. 31.5 %; OR=6.77; p<0.0001), and the
TOI (71.6 % vs. 24.1 %; OR=7.79; p<0.0001) [37]. These
QoL results conclusively indicate that EGFR-TKI should be
considered as the standard first-line therapy for advanced
EGFR-mutated NSCLC despite the lack of survival advantage.
EGFR-TKIs for EGFR-mutated patients with poor
performance status and advanced age
The multicenter phase II NEJ 001 study was undertaken to
investigate the efficacy and feasibility of gefitinib treatment
for advanced NSCLC patients harboring EGFR mutations
but who were ineligible for chemotherapy due to poor
performance status (PS) [39]. The overall response rate
was 66 %, and median PFS and MST were 6.5 months
and 17.8 months, respectively. PS improvement rate was
79 % (p<0.00005); in particular, 68 % of the 22 patients
improved from PS ≥3 at baseline to PS 0 or 1. (Fig. 3) Thus,
the “Lazarus Response”was observed in treatment-naïve, poor
PS patients with NSCLC and EGFRmutations [40]. In patients
with sensitive EGFR mutations but with extremely poor PS
(suspected MST less than 4 months with BSC), the difference
in benefit with or without gefitinib treatment was so marked
that a randomized phase III study to compare gefitinib to BSC
alonemay not be justified. This was the first occasion onwhich
changes in treatment guidelines were provoked by a phase II
study of NSCLC. Since previously there has been no standard
treatment for these patients with short life expectancy other
than BSC, examination of EGFR mutations as a biomarker is
also strongly recommended in this patient population.
In regard to so-called “fit” elderly patients harboring EGFR
mutations, the NEJ 003 phase II study [41] investigated
patients with chemotherapy-naïve history, a median age of
80 years (range: 75–87 years), and PS 0–1, who were treated
with gefitinib as a first-line treatment. The response rate was
74 %, and the median PFS and OS were 12.3 months and
33.8 months, respectively. Considering its strong antitumor
activity and mild toxicity, first-line gefitinib may be preferable
to standard chemotherapy in this population. However, a
phase III study comparing gefitinib to standard chemotherapy
may be needed to provide the final evidence of benefit in
advanced EGFR-mutated “fit” elderly patients.
Tarceva Lung cancer Survival Treatment (TRUST) [42]
was an open-label, phase IV study of unselected patients with
advanced NSCLC. In a subpopulation of elderly patients
(≥70 years) receiving first-line erlotinib (n=485) in TRUST
[43], the disease control rate was 79 %, median PFS was
4.57 months, and MST was 7.29 months. A total of 87
subpopulation patients (18 %) had an erlotinib-related adverse
event (AE); 4 % had a ≥3 grade erlotinib-related AE. Erlotinib
was effective and well-tolerated and may be considered for
unselected, elderly patients with advanced NSCLC who are
unsuitable for standard first-line chemotherapy or radiothera-
py. However, there have been few prospective studies of
erlotinib in advanced, EGFR-mutated, “fit” elderly patients.
EGFR mutation tests
Direct sequencing of EGFR requires histology obtained
by operation. The NEJ 001, NEJ 002, and NEJ 003
series all used the same EGFR mutation test, the pep-
tide nucleic acid-locked nucleic acid polymerase chain
reaction clamp (PNA LNA PCR clamp) [44–46]. This is
Fig. 3 Performance status (PS) improvement by gefitinib in the NEJ
001 Study. Each line shows changes of PS in a patient. [39]
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a technological innovation that can make not only
tissue-based assessment but also cytology-based assess-
ment of EGFR mutations. Briefly, genomic DNA frag-
ments surrounding mutation hot spots of the EGFR gene
are amplified by PCR in the presence of a clamp primer syn-
thesized from PNA with a wild-type sequence. This leads to
preferential amplification of the mutant sequence, which is
detected by a fluorescent primer that incorporates LNA to
increase specificity. As a result, a mutant EGFR sequence is
detected in the presence of a 100-fold wild-type sequence. Thus,
by the PNA LNA PCR clamp, a small number of EGFR
mutation-positive cancer cells are detected within 3 h. The
sensitivity and specificity of the PNA-LNA PCR clamp were
97 % and 100 %, respectively [46]. Therefore, EGFR testing by
the PNA LNA PCR clamp was possible in patients with
extremely poor PS and of advanced age.
In 2012, the performance, sensitivity, and concordance
among five EGFR tests of PCR-Invader®, PNA LNA PCR
clamp, direct sequencing, Cycleave™, and Scorpion
Amplification Refractory Mutation System (ARMS)® were
reported [47]. All tests, except direct sequencing, detected
mutation types at ≥1 % mutant DNA. Analysis success rates
were 91.4–100 %, and interassay concordance rates of suc-
cessfully analyzed samples were 94.3–100 %. It was con-
cluded that cytology-derived DNA is a viable alternative to
formalin-fixed paraffin-embedded (FFPE) tissue samples for
analyzing EGFR mutations.
It was clarified that frequencies of EGFR-mutated
NSCLC patients are approximately 31 % and 16.6 % in
Japan and Europe, respectively [46, 48]. In Japan, approx-
imately 50,000 patients were newly diagnosed as NSCLC in
1 year. In 2011, approximately 48,000 tests for EGFR muta-
tions were carried out under national health insurance, indi-
cating that most patients with NSCLC were screened in
Japan. Under circumstances where EGFR mutations,
EML4-ALK fusion gene, and RET fusion genes should be
tested, routine screening for all of these will be required
when making diagnosis of NSCLC.
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